Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31699802 | 0.86 | ALDH1A1 (0.43) | DPP4ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2858951 | 0.85 | HTR2A (0.32) | DPP4MGLLHTR2AHTR2C | |
| SCHEMBL10025682 | 0.84 | CFTR (0.33) | DPP4PARP1MGLLHTR2AHTR2C | |
| SCHEMBL14955967 | 0.83 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL10025712 | 0.82 | SCN9A (0.33) | DPP4HTR2AHTR2C | |
| SCHEMBL10025740 | 0.82 | MGLL (0.31) | MGLLHTR2AHTR2C | |
| SCHEMBL10025673 | 0.81 | OPRD1 (0.33) | DPP4MGLLALDH1A1KMT2A | |
| SCHEMBL31700184 | 0.81 | NPSR1 (0.39) | NPSR1CHRM3ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL14955894 | 0.81 | MGLL (0.31) | MGLLHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL31700196 | 0.80 | NPSR1 (0.38) | NPSR1CHRM3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | disclosed |
| CN-118930551-B | Process for preparing beta-aminopyrazine acetate | 江苏恒瑞医药股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118930551-A | Process for preparing beta-aminopyrazine acetate | 江苏恒瑞医药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118547024-A | Ragliptin intermediate, preparation method and application thereof | 弈柯莱生物科技(集团)股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-30 | — | — | US | disclosed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-117177958-A | Small molecule modulators of alveolar type 2cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2023-12-05 | — | — | CN | disclosed |
| EP-4281439-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-2604610-B1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| EP-2604610-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019430-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012019427-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DPP4 1527/4885PARP1 1794/4885NPSR1 2055/4885 |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885PARP1 3234/4885NPSR1 3646/4885 |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PARP1, PARP2, PARP4 | DPP4 1054/4885PARP1 1/4885NPSR1 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.